4,5-二甲基水杨酸 | 58138-52-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4,5-二甲基水杨酸
• 英文名称: 4.5-Dimethyl-salicylsaeure
• 英文别名: 4,5-Dimethylsalicylic acid；2-hydroxy-4,5-dimethylbenzoic acid
• CAS: 58138-52-6
• 化学式: C₉H₁₀O₃
• mdl: MFCD12196123
• 分子量: 166.177
• InChiKey: VFIVMIIQIYPVCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,5-二甲基水杨酸 在 吡啶 、 咪唑 、 sodium tetrahydroborate 、 ozone-containing oxygen 、 四甲基乙二胺 、 三甲基锍 、 三甲基铝 、 叔丁基锂 、 lithium carbonate 、 sodium hydride 、 溶剂黄146 、 N,N-二乙基苯胺 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.84h， 生成
  参考文献：
  名称：

  Structure−Activity Relationships for Inhibition of Inosine Monophosphate Dehydrogenase by Nuclear Variants of Mycophenolic Acid

  摘要：

  Structure-activity relationships in the region of the phthalide ring of the inosine monophosphate dehydrogenase inhibitor mycophenolic acid have been explored. Replacement of the lactone ring with other cyclic moieties resulted in loss of potency, especially for larger groups. Replacement of the ring by acyclic substituents also indicated a strong sensitivity to steric bulk. A phenolic hydroxyl group, with an adjacent hydrogen bond acceptor, was found to be essential for high potency. The aromatic methyl group was essential for activity; the methoxyl group could be replaced by ethyl to give a compound with 2-4 times the potency of mycophenolic acid in vitro and in vivo.

  DOI：

  10.1021/jm9603633
• 作为产物：
  描述：

  2-羟基-4,5-二甲基-苯甲醛 在 氢氧化钾 、 sodium hydroxide 作用下， 生成 4,5-二甲基水杨酸
  参考文献：
  名称：

  REACTION OF ANHYDROSEPEDONIN WITH ALKALI SYNTHESIS OF A DEGRADATION PRODUCT AND SOME RELATED DIMETHYLHYDROXYBENZOIC ACIDS

  摘要：

  从无水石蕈酮与碱反应中分离出两种产物，并鉴定为3-羟基-5-甲基苯甲酸和3,4-二甲基-5-羟基苯甲酸。后一化合物的结构通过明确的合成得到确认。在这项工作中，还制备了从o-二甲苯衍生的其余o-和m-羟基苯甲酸。

  DOI：

  10.1139/v64-010

文献信息

• [EN] LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM<br/>[FR] PROMÉDICAMENTS DE LEVORANOL ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2018191472A1

  公开（公告）日：2018-10-18

  The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to levorphanol ((-)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.

  目前描述的技术提供了一种或多种羟基酸、聚乙二醇和维生素化合物与左旋吗啡醇((-)-17-甲基吗啡-3-醇)在化学上结合形成新型前药和左旋吗啡的组合物。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• [EN] DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM<br/>[FR] PROMÉDICAMENTS DE DEXTRORPHANE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2018191477A1

  公开（公告）日：2018-10-18

  The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.

  目前描述的技术提供了将一种或多种羟基酸、聚乙二醇和/或维生素化学共轭到右旋丙啡醇（(+)-17-甲基吗啡酮-3-醇）上，形成新型前药和右旋丙啡醇组合物的配方。
• BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF
  申请人：Mickle Travis

  公开号：US20110002990A1

  公开（公告）日：2011-01-06

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了包含芳基羧酸与羟考酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型羟考酮前药/组合物，包括苯甲酸酯和杂环芳基羧酸，具有降低滥用羟考酮潜力的特性。该技术还提供了治疗患者的方法、制药工具包和合成本技术共轭物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof
  申请人：KemPharm, Inc.

  公开号：US20150335759A1

  公开（公告）日：2015-11-26

  The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

  目前描述的技术提供了治疗患有中度至严重疼痛、麻醉药或阿片类药物滥用或戒断症状的患者的方法。目前描述的方法是通过向患者施用包含对乙酰氨基酚和苯甲酸盐羟考酮盐酸盐的药物有效量的组合物来实施的。与未结合的羟考酮相比，该组合物具有减少的副作用。